---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-257937"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2022-10-05T23:59:59+00:00"
generated_at: "2026-06-23T05:24:50.860830+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics ETX-155 update; Phase 2a MDD on track for Q1 2023; cash $129.8M

## Summary
- Cash, cash equivalents and investments of $129.8M as of Sept 30, 2022 (includes $6.2M tax reimbursements); funds operations into 2025.
- ETX-155 60mg single-dose exposures in Phase 1 PK trial consistent with prior trials; low PSE exposures within previously reported variability.
- Company to evaluate 75mg repeat dose in ongoing Phase 1 PK trial; final results expected Q4 2022.
- Phase 2a MDD trial to initiate Q1 2023; topline data mid-2024. PSE trial not reinitiated; FOS development continues.
- Kv7 program: two pre-candidates scaling up for IND-enabling studies Q1 2023; Phase 1 studies H1 2024. GAD program discontinued.

## SEC filing metadata
- accession: 0001193125-22-257937
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2022-10-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312522257937/0001193125-22-257937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312522257937/d401397d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-257937
- JSON: https://secwatch.observer/filing/0001193125-22-257937.json
- Plain text: https://secwatch.observer/filing/0001193125-22-257937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.